XML 38 R25.htm IDEA: XBRL DOCUMENT v3.21.2
License, Collaboration and Other Significant Agreements (Tables)
 9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Revenues Recognized from License, Collaboration and Other Significant Agreements
During the three and nine months ended September 30, 2021 and 2020, the Company recognized the following revenues from its license, collaboration and other significant agreements and had the following deferred revenue balances as of September 30, 2021:
 
 Three Months Ended September 30,Nine Months Ended September 30,
 2021202020212020
License, Collaboration and Other Revenue:(in thousands)(in thousands)
MTPC Agreement$2,555 $373 $7,167 $15,373 
Otsuka U.S. Agreement6,144 16,256 28,988 80,721 
Otsuka International Agreement1,860 7,243 13,532 39,445 
Total Proportional Performance Revenue$10,559 $23,872 $49,687 $135,539 
JT and Torii1,444 1,183 4,093 4,049 
MTPC Other Revenue— 541 73 4,723 
Total License, Collaboration and Other Revenue$12,003 $25,596 $53,853 $144,311 
Deferred Revenues During the three and nine months ended September 30, 2021 and 2020, the Company recognized the following revenues from its license, collaboration and other significant agreements and had the following deferred revenue balances as of September 30, 2021:
 September 30, 2021
 Short-TermLong-TermTotal
Deferred Revenue:(in thousands)
MTPC Agreement$4,883 $— $4,883 
Otsuka U.S. Agreement$6,308 $16,664 $22,972 
Otsuka International Agreement4,501 6,623 11,124 
Vifor Agreement— 4,678 4,678 
Total$15,692 $27,965 $43,657 
Changes in Contract Assets and Liabilities
The following table presents changes in the Company’s contract assets and liabilities during the nine months ended September 30, 2021 and 2020 (in thousands):
Nine Months Ended September 30, 2021Balance at
Beginning of
Period		AdditionsDeductionsBalance at End
of Period
Contract assets:    
Accounts receivable(1)$3,045 $38,795 $(20,427)$21,413 
Prepaid expenses and other current assets$1,722 $1,725 $(5)$3,442 
Contract liabilities:
Deferred revenue$40,559 $65,890 $(62,792)$43,657 
Accounts payable$7,227 $— $(7,227)$— 
Accrued expenses and other current liabilities$10,000 $— $— $10,000 
Nine Months Ended September 30, 2020
Contract assets:
Accounts receivable(1)$15,822 $143,148 $(156,209)$2,761 
Prepaid expenses and other current assets$— $1,248 $— $1,248 
Contract liabilities:
Deferred revenue$72,950 $110,295 $(131,551)$51,694 
Accounts payable$— $10,097 $(5,651)$4,446 
Accrued expenses and other current liabilities$— $615 $(615)$— 
 
(1)Excludes accounts receivable from other services related to clinical and regulatory activities performed by the Company on behalf of MTPC that are not included in the performance obligations identified under the MTPC Agreement as of September 30, 2021 and 2020 and December 31, 2020 and 2019. Also excludes accounts receivable related to amounts due to the Company from product sales which are included in the accompanying unaudited condensed consolidated balance sheet as of September 30, 2021 and December 31, 2020.
Revenue Recognized Resulting from Changes in Contract Assets and Contract Liabilities
During the three and nine months ended September 30, 2021 and 2020, the Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the respective periods (in thousands):
 
 Three Months Ended September 30,Nine Months Ended September 30,
Revenue Recognized in the Period from:2021202020212020
Amounts included in deferred revenue at the beginning of the period$9,159 $6,537 $20,363 $29,203 
Performance obligations satisfied in previous periods$— $20,648 $— $21,346